









Markets
/
Stocks
/
nasdaq-xoma
/

XOMA Royalty Corp

XOMA

View Detailed Chart

26.960USD

+0.850+3.26%

Close 07/03, 13:00（ET）Quotes delayed by 15 min

322.25MMarket Cap

LossP/E TTM



XOMA Royalty Corp

26.960

+0.850+3.26%

Company

Intraday

30m

Today

+3.26%

5 Days

-1.93%

1 Month

+7.84%

6 Months

+0.52%

Year to Date

+2.59%

1 Year

+4.09%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 4 analysts

BUY

Current Rating

64.667

Target Price

139.86%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

XOMA Royalty Corp

XOMA

Roku Inc

ROKU

Live Nation Entertainment Inc

LYV

TKO Group Holdings Inc

TKO

Warner Music Group Corp

WMG

Imax Corp

IMAX

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(3)

Buy(9)

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.167

Buy

RSI(14)

57.633

Neutral

STOCH(KDJ)(9,3,3)

65.488

Neutral

ATR(14)

1.386

High Vlolatility

CCI(14)

55.676

Neutral

Williams %R

26.216

Buy

TRIX(12,20)

0.281

Sell

StochRSI(14)

54.963

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

26.420

Buy

MA10

26.473

Buy

MA20

25.581

Buy

MA50

25.205

Buy

MA100

23.516

Buy

MA200

25.904

Buy

News

More news coming soon, stay tuned...

Company

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The Company also acquires milestone and royalty revenue streams on late-stage or commercial assets.

Ticker SymbolXOMA

CompanyXOMA Royalty Corp

CEOMr. Owen P. Hughes, Jr.

Websitehttps://www.xoma.com/